Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Third Quarter 2024 Financial Results

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...
November 02, 2021 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data...